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When treating older adults, a main factor to consider is physical frailty. Because speciﬁc assessments in
clinical trials are frequently lacking, critical appraisal of treatment evidence with respect to functional
status is challenging. Our aim was to identify and categorize assessments for functional status given in
clinical trials in older adults to allow for a retrospective characterization and indirect comparison of
treatment evidence from these cohorts. We conducted 4 separate systematic reviews of randomized and
nonrandomized controlled clinical trials in older people with hypertension, diabetes, depression, and
dementia. All assessments identiﬁed that reﬂected functional status were analyzed. Assessments were
categorized across 4 different functional status levels. These levels span from functionally not impaired,
slightly impaired, signiﬁcantly impaired, to severely impaired/disabled. If available from the literature,
cut-offs for these 4 functioning levels were extracted. If not, or if the existing cut-offs did not match the
predeﬁned functional levels, cut-off points were deﬁned by an expert group composed of geriatricians,
pharmacists, pharmacologists, neurologists, psychiatrists, and epidemiologists using a patient-centered
approach. We identiﬁed 51 instruments that included measures of functional status. Although some of
the assessments had clearly deﬁned cut-offs across our predeﬁned categories, many others did not. In
most cases, no cut-offs existed for slightly impaired or severely impaired older adults. Missing cut-offs or
values to adjust were determined by the expert group and are presented as described. The functional
status assessments that were identiﬁed and operationalized across 4 functional levels could now be used
for a retrospective characterization of functional status in randomized controlled trials and observationalcomprises Christine A.F. von
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Fig. 1. (A) Beneﬁt-risk relation for treatment regimens
vulnerable older people.studies. Allocated categories only serve as approximations and should be validated head-to-head in
future studies. Moreover, as general standard, upcoming studies involving older adults should include
and explicitly report functional impairment as a baseline characteristic of all participants enrolled.
 2018 AMDA e The Society for Post-Acute and Long-Term Care Medicine. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).To optimally tailor drug therapy in older adults to their speciﬁc
needs, it is desirable to identify, evaluate, and critically appraise the
available evidencewith respect to not only chronological age but other
factors. Epidemiologic longitudinal studies have demonstrated that
functional status, disability, or frailty were more predictive for mor-
tality or other relevant endpoints than, for example, the number of
comorbidities or age alone.1e4 As a consequence, at least some
guideline committees are already working on separate recommen-
dations for functionally impaired older adults.5 However, evidence is
still very limited because of the exclusion of functionally dependent
patients from clinical studies and because it is impossible to compare
cohorts in treatment studies with respect to functional status.6,7
Although the International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use (ICH) has recom-
mended to include frail older adults in clinical trials in 1993,8 most
studies have not yet followed this advice. A few studies, however, did
include frail older people. Recent examples are the Systolic blood
PRessure INtervention Trial (SPRINT) and the HYpertension in the Very
Elderly Trial (HYVET) for the treatment of arterial hypertension. Both
have demonstrated positive effects of tighter blood pressure control,
even in prefrail and apparently frail older adults, identiﬁed by the
frailty index.9,10 This does not resemble ﬁndings from observational
studies that show that the more severely impaired may not beneﬁt
anymore.3,4 These uncertainties often spark great controversies as
observed with the development of the Joint National Committee (JNC-
8) guideline on arterial hypertension.11e13 The call for inclusion of frail
people has been repeated in the 2007 statement paper by the Euro-
pean Medicines Agency (EMA),14 such as the statement on points to
consider on frailty (EMA/CHMP/778709/201515) or the EU DIRECTIVE
2001/83/EC.16 Frailty, however, is an extremely heterogeneous term,
still awaiting an international consensus deﬁnition. It is accepted that
frailty can be considered a vulnerable state that often results in
disability, loss of autonomy, and dependency. Frailty is, therefore,
subsequently tightly linked to functional status.17
Functional status can be characterized by measures of activities of
daily living, performance-based tests on physical functioning, or
interview-based questionnaires on functional abilities.18 Functionalbeneﬁt
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that carry high risk for vulnerableparameters can also be found in all tools on physical frailty and a
variety of assessments addressing functional status have been devel-
oped and included in studies.19 In addition to the International Clas-
siﬁcation of Diseases (ICD), the WHO has developed the International
Classiﬁcation of Functioning, Disability and Health (ICF) to standardize
the assessment of health and disability across all social and cultural
contexts.20 Impaired functional status may result in dependency and
disability, in line with the disablement process model by Verbrugge
and Jette21 and the ICF framework.
Nobody would ever question that functional status at least
implicitly inﬂuences everyday treatment decisions in older people. As
an example, high-risk treatments such as chemotherapy would in
most cases not be considered appropriate for functionally impaired
older people (Figure 1A). Our hypothesis is that for less aggressive
treatments, the beneﬁt-harm turnover, where the risk for harm is
greater than the expected beneﬁt, shifts toward the functionally
severely impaired and disabled older people, but that it still does exist
and has to be considered for most treatment decisions (Figure 1B).
Therefore, all information on functional status that can be found in
available clinical trials and observational studies should be used to
classify treatment evidence across the functional trajectory.
For that purpose, all assessments that include a sufﬁcient number
of parameters on functional status could be used as proxies to
approximately characterize the population of interest according to
their functional level. This also applies to assessments on physical
frailty. In the following, we will explain our rationale and why we are
conﬁdent that this approach would be of use for the scientiﬁc com-
munitydat least until all new treatment studies include appropriate
tests on functional status as well as a signiﬁcant number of older
adults with functional impairments.Methods
The Medication and Quality of Life research group is a German
network by the Ruprecht-Karls University of Heidelberg, the Albrecht-
Ludwigs University of Freiburg i. Br., and Ulm Universit. It consists ofFit/
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older people. (B) Beneﬁt-risk relation for treatment regimens that carry low risk for
S. Brefka et al. / JAMDA xxx (2018) 1e9 3geriatricians, internists, epidemiologists, neurologists, psychiatrists,
clinical pharmacologists, and clinical pharmacists. The overall goal of
the project is to identify the highest level of evidence for drug treat-
ment of older people across different functional status levels and
include this evidence in computer-adapted decision tools, taking into
account individual preferences in order to facilitate treatment de-
cisions in everyday clinical life. The ﬁrst 2 work packages are devoted
to the compilation of systematic literature reviews on common
chronic diseases for older adults, beginning with arterial hyperten-
sion,22 and the categorization of this evidence across different func-
tional status levels. As part of 3 ongoing systematic reviews of
randomized and nonrandomized controlled clinical trials in older
people with hypertension, dementia, and diabetes, all assessments
reﬂecting functional status identiﬁed in such trials were collected.Deﬁnition of Functional Categories
In order to rate the evidence across deﬁned functional levels, the
group ﬁrst had to agree on the optimal and minimal number of
categories needed to differentiate between treatments across
different disease entities. A consensus was reached on categorizing
functional status across the following 4 different levels to optimally
account for ﬁndings from different clinical trials involving older adults
and to account for clinical feasibility: (1) functionally independent,Independent P
u
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Fig. 2. Proposed functional status levels for the retro(2) slightly impaired, (3) signiﬁcantly impaired, and (4) severely
impaired/disabled/dependent older adults. Figure 2 describes the
prototypic person for each category. The category on the disabled,
functionally severely impaired older adults includes all of those that
are mostly or totally dependent on help by relatives or professionals,
and often live in long-term care or nursing homes. Many assessments,
especially those on frailty, lack information about this last (disability/
dependency) category, which we consider necessary in order to
discuss treatment recommendations for several slowly progressing
chronic diseases.Identiﬁcation of Functional and Physical Frailty Assessments
As part of 3 systematic literature reviews within a larger project on
available evidence for drug treatment of frail older adults,22 we
identiﬁed assessments of physical function or physical frailty that
were used in any of these studies. In addition, we conducted a
nonsystematic search using the search terms function(al) assessment,
function(al) measure, function(al) test, frailty assessment, frailty score,
and frailty scale to identify additional indices, scores, and function-
ality/frailtymeasures that are related to functionality/frailty or, at least
to some extent, relate to functional decline and/or disability. Our
expert group added further instruments that were not found by the
mentioned procedures. No additional restrictions were made.erson without relevant impairments, with 
nrestricted mobility, no problems to perform 
elf care and usual acvies 
erson with slight problems in walking, 
light problems to perform all acvies of daily 
iving including instrumental acvies, but sll 
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elp by an assisng person in several acvies
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spective characterization of study populations.
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Status
Following our concept, all applicable assessments had to report on
physical functioning/functional status, and function measures should
contribute substantially to the overall assessment or be reported
separately. Ideally, most measures or questionnaires should be related
to lower extremity and mobility domains because of their greater
impact on activities of daily living and dependency.23 All tools
complying with these requirements were rated as functional quality
category A. Assessments that contained rather few functional or
physical frailty items or which only implicitly addressed these items
(eg, within a rating of general health such as ASA, Karnofsky, or ECOG
Performance Scores) were rated as category B. All assessments that
solely addressed different concepts such as physical activity or
morbidity or that did not allow differentiation of 4 functional levels
according to our method were excluded.
After identifying the instruments, we proceeded to extract their
cut-offs for the 4 deﬁned functional levels. For those instruments
where no cut-off values were established from the literature that
resembled our predeﬁned categories, or where the existing cut-offs
did not match our functional concept, cut-offs based on functional
status were proposed following these steps:
1. Critical evaluation of items, taking into account the maximum
and minimum item results and item weights, the used scoring
system and its clinical interpretation, followed by determining
what best possible result a person could optimally obtain in a
given functionality category in each item.
2. Determination of the upper cut-off points by counting the re-
sults, whereas the lower cut-offs result from the upper ones of
the next lower functional status level.
3. Discussion and review of the results within the expert group
and ﬁnal statement.
With the resulting proposal, studies for diverse treatments in
older people could be reevaluated according to functional statusScreening of n = 67037 ab
frailty and funcƟonal asse
Final selecƟon:
n = 51 assessmen
n = 29 excluded for
diﬀerent reasons (see
Supplement
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Fig. 3. Flow chart of the identiﬁcationof participants in order to construct Geriatric evidence maps.
These maps should be clearly separated for functional status and
for evidence levels according to standard approaches. They would
list the number of studies showing a positive effect, neither a
positive nor a negative effect, or a negative effect of a certain
treatment for clinically relevant outcomes depending on func-
tional status.Results
A total of 67,037 studies were screened as part of the 3 systematic
reviews as described above. Complemented by the result of the non-
systematic literature search and the additions of the expert group, 80
assessments were identiﬁed and critically evaluated. Twenty-nine
assessments were excluded, and 51 were rated according to our pre-
deﬁned method. Forty-seven were assigned to category A and 4 to
category B (Figure 3).
Possible cut-off points for this nonconclusive list of 51 instruments
are presented in Tables 1 and 2. For better overview, frailty-oriented
assessments are presented separately in Table 1, whereas Table 2
summarizes all other assessments that include functional status
items and could be classiﬁed across our predeﬁned functional
categories. A list of included and excluded assessments with com-
ments on the reasons for inclusion or exclusion can be found in
Supplement 1. Ratings of individual assessment items are provided in
Supplement 2.
Available cut-offs for all 4 deﬁned functional levels were consid-
ered present in 5 of 51 assessments; 6 assessments had only pre-
deﬁned cut-offs for some of the functional levels (eg, without
discrimination between “functionally independent” and “functionally
slightly impaired”) and it was not possible to calculate the missing
cut-offs. The remaining assessments were partly (n¼ 3) or completely
(n ¼ 33) processed according to our algorithm. For the clinical judg-
ment scores (n ¼ 4), we had to estimate which clinical conditions
mostly ﬁt the 4 functional levels.stracts for
ssments
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process of included assessments.
Table 1
Frailty Indices and Scores to Categorize Patients According to Their Functional Status/Frailty Stage*
Scores and Indices/
Functional Category
Functionally
Independent
Functionally
Slightly
Impaired
Functionally Signiﬁcantly
Impaired/Partially
Dependent
Functionally Severely Impaired/
Disabled/Mostly or Totally
Dependent
Functional
Quality
Category
Comprehensive Assessment of Frailty
(CAF)43,44
1-5 6-22 23-30 31-35 A
Cardiovascular Health Study (CHS,
Fried) Frailty Scale17
0 0-2 3 4-5 A
Clinical Frailty Scale45 1-2 3-4 5-6 7-8 A
Frailty predicts death One year after
Elective Cardiac Surgery Test
(FORECAST)43,46
1 2-6 7-12 13-14 A
Gill Frailty Measure47 10 s to walk 3.0 m forth and
back as quickly as possible
and able to stand up from a
chair with arms folded
>10 s to walk 3.0 m forth and back as
quickly as possible or unable to stand
up from a chair with arms folded
>10 s to walk 3.0 m forth and back as
quickly as possible and unable to
stand up from a chair with arms
folded
A
Program of Research on Integration of
Services for the Maintenance of
Autonomy (PRISMA)d748
0 1-2 3 4-7 A
Frail Non-Disabled (FiND)
Questionnaire49,50
0 0-1 (A/B) 2 (A/B) þ 0-1 (C/D/E) ¼ 2-3 2 (A/B) þ 2-3 (C/D/E) ¼ 4-5 A
Fatigue, Resistance, Ambulation,
Illnesses, Loss of Weight (FRAIL)
Scale51
0 0-1 2 3-5 A
Frailty/Vigor Assessment52 <4 frailty criteria, 4 vigor
criteria
4 frailty criteria, 3 vigor criteria >4 frailty criteria, 3 vigor criteria A
FRail Elderly Support researcH group
(FRESH) Screening Instrument53
0 0-2 3 4-5 A
Gérontopôle Frailty Screening Tool54 0 1 2 A
Groningen Frailty Indicator55 0 0-1 2-4 5-15 A
MacArthur Study of Successful Aging
(MSSA)56
0 0-3 4 5 A
Study of Osteoporotic Fractures (SOF)57 0 1 2-3 A
Tilburg Frailty Indicator (Part B)58 0 1-4 5 6-15 A
Canadian Study on Health and Aging
(CSHA, Rockwood) Frailty Index (min.
30 items)41
0-0.1 >0.1 and  0.21 >0.21 and  0.45 >0.45 A-By
*For the determination of cut-offs: see supplement 2 and methods above.
yDepends on the index used in the study that is to be examined because index is composed individually in every study. Index should, therefore, be scrutinized with respect
to items reﬂecting functional status.
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We identiﬁed and categorized 51 assessments across 4 predeﬁned
functional status levels, which could now be used to characterize a
study population according to functional status. We also deﬁned
categories that allow for quality ratings of all functional assessments
identiﬁed. With our proposed approach, evidence maps for certain
treatments in older people could be constructed, clearly separated for
functional status and for evidence levels according to standard
approaches.
To our knowledge, such an approach has not been taken before.We
believe that our results can be useful for improving the critical
appraisal of the available literature by setting the results of clinical
trials into a functional perspective. This would improve information
for stakeholders and health professionals on the (lack of) evidence on
medical treatments across a trajectory of functionally independent
older adults versus those with functional impairments up to disability
and functional dependency.
Following our hypothesis, the beneﬁt-risk relation of certain
treatments changes along the trajectories of functional status
depending on the clinical condition. Implications of this observation
can be exempliﬁed by different guidelines on arterial hypertension
that recommend different systolic blood pressure targets for older
people. Although most of them still endorse 150 mmHg for those
80 years old, newer trials such as the SPRINT study shatter these
recommendationsdeven in frail older people. Frailty in SPRINT was
measured by amodiﬁed frailty index as proposed by Rockwood.24 Thisfrailty indexwas generated out of 37 items, of which only 4 itemswere
related to functional status (gait speed, washing and dressing com-
bined, limitations with moderate activities, and climbing a ﬂight of
stairs), applying a multidimensional approach to increasing vulnera-
bility. According to our functional approach, it would be rated category
B and should be critically appraised in evidence maps focusing on
functional status. Therefore, SPRINT (or HYVET9) might not contradict
ﬁndings from observational trials that included participants with
higher functional impairments or disability such as the PARTAGE
study in nursing homes3 or a population-based study using data from
the National Health and Nutrition Examination Survey.4 Some
guidelines have taken up these ﬁndings. For example, the 2013 ESH/
ESC guideline recommends that in frail older adults blood pressure
should be lowered as tolerated.25 These results seem to be comparable
to other chronic diseases such as chronic obstructive pulmonary dis-
ease26 or osteoporosis,27 where standard treatments could be rec-
ommended up to frail, but possibly not functionally severely impaired,
activities of daily livingedependent older people. When treatments
are known to possibly cause more severe adverse drug reactions,
deviations from standard recommendations in older people could
even become necessary earlier during the functional trajectory. Ex-
amples can be found for antidepressant medication of major depres-
sive disorders,28 or even more pronounced for chemotherapy29 and
treatment of diabetes with an increased risk of hypoglycaemia.30
Frailty instruments were also included and rated according to our
approach. Although many focus on physical frailty and, therefore,
include many functional status measures, many others do not. The
Table 2
Other Indices and Scores to Categorize Patients According to Their Functional Status*
Scores and Indices/Functional Category Functionally
Independent
Functionally
Slightly
Impaired
Functionally Signiﬁcantly
Impaired/Partially
Dependent
Functionally Severely
Impaired/Disabled/
Mostly or Totally
Dependent
Functional
Quality
Category
Barthel ADL-Index59 100 75-100 45-70 0-40 A
Berg Balance Scale60 55-56 38-54 9-37 8 A
Bristol ADL Scale61 0 1-7 8-36 37 A
Functional Independence Measure (FIM)62 126 105-126 64-104 18-63 A
5-Chair-Rise63 15 s >15 s Unable A
Gait Speed64,65 1.0 m/s <1.0 and  0.8 m/s <0.8 and  0.5 m/s <0.5 m/s A
Groningen Activity Restriction Scale (GARS)66 18-21 22-36 37-68 69 A
Handgrip strength67,68 32 kg _
20 kg \
26-31.9 kg _
16-19.9 kg \
19-25.9 kg _
15.3-15.9 kg \
18.9 kg _
15.2 kg \
A
Interview for Deterioration in Daily Living
Activities in Dementia (IDDD)69
36 (initiation),
0 performance
36 (initiation),
0-2 performance
36 (initiation),
3-36 performance
36 (initiation), 37
performance
A
Katz ADL Index70 6 4-6 2-3 0-1 A
Knee extensor strength71 3.0 Nm/kg <3.0 Nm/kg A
Lawton IADL Index72 8 8 4-7 0-3 A
Minimum Data Set (MDS) ADL73,74 0 0-3 4-18 19 A
Modiﬁed Physical Performance Test (MPPT)75 32-36 19-31 3-18 2 A
Nürnberger Alters-Alltagsaktivitäten (NAA)
Scale76
20 20-24 25-39 40 A
Nürnberger Alters-Beobachtungen (NAB)
Scale76
15 15-19 20-29 30 A
Physical Self-Maintenance Scale (PSMS) ADL
(range 0-6)72
6 3-6 1-2 0 A
Physical Self-Maintenance Scale (PSMS) original
observer-rated version (range 6-30)77
6 6-10 11-21 22 A
Physical Self-Maintenance Scale (PSMS) self-
rated version (range 8-24)78
24 21-24 10-20 9 A
6-Minute-Walk79 >300 m 300 m A
Short Physical Performance Battery (SPPB)80 10-12 7-9 3-6 0-2 A
Timed Up and Go81 <10 s 10 and < 20 s 20 and < 30 s 30 s A
Vulnerable Elders Survey (VES) 1382,83 0 or 3 (if participant
gets 3 points for age)
0-6 or 3-9 (if participant
gets 3 points for age)
7-10 or 10 (if participant
gets 3 points for age)
A
Alzheimer’s Disease Cooperative Study (ADCS)
ADL Scale84,85
78 72-78 38-71 37 A
Disability Assessment for Dementia (DAD)86,87 100% >90%-100% >47.5%-90% 47.5% A
Epic Assessment System (EASY) Care88 49-50 51-59 60-80 81 A
Multidimensional Prognostic Index (MPI)89 0-0.33 0.34-0.66 0.67-1.0 A
Short Form (SF) 12 (PCS)90 50.5-56.6 40.3-50.4 29.7-40.2 29.6 A
Short Form (SF) 36 (PCS)91e93 48.7-64.0 29.6-48.6 21.2-29.5 21.1 A
Score Hospitalier d’Evaluation du Risque de
Perte d’Autonomie (SHERPA)94
0 0-1 1.5-3 3.5-11.5 A
Triage Risk Screening Tool (TRST)95 0 0-1 2-5 A
American Society of Anesthesiologists (ASA)
Score96
I-II II-III III-IV IV-V B
Eastern Cooperative Oncology Group (ECOG)97 0 1-2 3-4 B
Falls Efﬁcacy ScaleeInternational (FES-I)98 16 17-32 33-48 49-64 B
Karnofsky Index99 100 80-90 60-70 10-50 B
(I)ADL, (instrumental) activities of daily living.
*For the determination of cut-offs: see supplement 2 and methods above.
S. Brefka et al. / JAMDA xxx (2018) 1e96heterogeneity of frailty deﬁnitions is huge. And because frailty has
been deﬁned primarily clinically, its etiology has been discussed in
comparable complexity as its operationalization. Potential causative
pathways that have been hypothesized include sarcopenia,31 senes-
cent immune remodeling,32 neurodegeneration,33 or even poly-
pharmacy.34 Therefore, frailty assessments sometimes even include
biomarkers35 or psychological parameters such as cognition
(Edmonton Frail Scale36). This heterogeneity has led to the deﬁnition
of derived concepts such as cognitive frailty,37 cardiovascular frailty,38
or social frailty.39 The most common assessment instruments are the
clinical phenotype model by Fried (the Frailty phenotype, often also
called physical frailty)17 and the deﬁcit model by Rockwood and
Mitnitski (the Frailty Index).40,41 Although the frailty phenotype
model includes mainly functional status items, the estimated frailty
index according to the deﬁcit model depends very much on the pa-
rameters collected in each study. As a result, it hardly ever includes thesame parameters and, for example, as demonstrated above, in the
SPRINT study mostly assesses multimorbidity. Thus, in every study
where deﬁcit models are used to characterize frail older people, these
models have to be judged individually according to our proposed
criteria.
Following strictly our concept of functional impairment, we
excluded those frailty scores that did not contain at least 25% physical
functionality. Furthermore, not all models span the full range from no
or little impairment to disability and dependency. Even physical frailty
models such as the clinical phenotype by Fried usually do not include
dependency, with the consequence of limited applicability to identify
these functional states. Because treatment recommendations for
many chronic diseasesmight not be different for frail older adults until
evident disability occurs, as shown above, we need to span a wider
range of functional status including dependency. Nevertheless, in the
context of early identiﬁcation of (imminent) frailty and prevention of
S. Brefka et al. / JAMDA xxx (2018) 1e9 7functional decline, frailty assessments and their implementation and
application are still essential.
When rating evidence according to functional levels, several out-
comes should be considered. An individual’s personal preferences can
change along the life course and, apart from overall survival, can range
from longevity to quality of life or disability-free life years.42 Terms
such as quality-adjusted life years (QALYs) and disability-adjusted life
years (DALYs) have to be mentioned in this context as appropriate
endpoints. As an example, frequent falls because of hypotensionmight
be more threatening to an individual person than the risk of suffering
a cerebral ischemia within the next years. However, cerebral ischemia
can have catastrophic consequences, and physicians are responsible
for clearing up any misunderstandings about the disabling results of a
major stroke before they accept to withhold essential treatment.
Guidelines including stratiﬁcation of treatment goals according to
physical frailty or functionality could support these clinical decisions.
If no evidence for the functionally severely impaired is available,
treatment choices should be made according to the available disease-
speciﬁc guidelines. These considerations very clearly demonstrate the
need to be as precise as possible when critically appraising evidence
for individual diseases in older adults, and that tailoring treatment
approaches according to chronological age never really hits the mark.
Strengths and Limitations
Because of the non-systematic approach of our review, Tables 1
and 2 summarize only the most common instruments used in clin-
ical settings and do not represent an exhaustive list. Nevertheless, our
study proposes a new approach to disentangle functionality levels
across different instruments and new instruments can always be
added, following our approach. The decision that an assessment or
score sufﬁciently reﬂects physical function is always contestable. We
are aware that several proposed assessments do not primarily mea-
sure functional status and should be interpreted with caution and
within the individual context. For certain indices the cut-off values
were very difﬁcult to determine and consensus not easy to reach.
Especially, disentangling the functional levels “independent” and
“slightly impaired” was not always possible or sometimes only
resulted in very small differences. For example, when evaluating the
Lawton IADL, we determined a difference of only 1 point between a
functionally independent and a functionally signiﬁcantly impaired
patient, taking into account that only 1 of the inquired instrumental
activities of daily living would most likely not be achievable for a
signiﬁcantly impaired older person, which is “taking care of all
shopping needs independently.”
Tables 1 and 2 also include some assessments that do not explicitly
measure functionality but provide information about general health
such as the ASA Score and Karnofsky Index. In addition, from a con-
ceptual point of view, a proxy-rated activities of daily living index
cannot be compared with performance-based assessments such as
gait speed or handgrip strength. However, this proposal has to be
considered a reasoned viewpoint to provoke and inform further dis-
cussion about necessary changes in clinical trial planning for older
people. In addition, because of the frequent lack of measurements on
functionality, these instruments could still help to retrospectively
characterize the study population in relation to the participants’
functional limitation and/or dependency better than by simply using
age as the primary stratifying variable.We encourage identifyingmore
suitable assessments and adding them to our list by evaluation ac-
cording to our proposed method. We are aware that cognitive
impairment and mental health (eg, depression) are not explicitly
included by focusing on functional status. However, as mentioned
above, deﬁcits in these domains also may lead to functional decline
and disability downstream within the disablement process. Our
strong focus on physical function allows for rating andcharacterization of all kinds of different treatments from antihyper-
tensives to antidementive or antidepressant therapies.
Conclusion
According to the available evidence, differences in treatment ef-
fects and outcomes seem to affect mostly individuals with (severe)
functional impairments and disability. Most clinical trials and obser-
vational studies in older adults have not included appropriate as-
sessments to allow for a functional categorization of their participants.
However, they might provide some other information about func-
tional status, which could be used as a proxy to rate the population
under study. For the retrospective characterization of frail and func-
tionally impaired older people in clinical trials and observational
studies, we propose cut-off points for 51 existing assessments on
functional status and physical frailty across 4 common categories. The
scientiﬁc and clinical community should strive for inclusion of
appropriate assessments on functionality in every future study in
order to clearly identify any of the following categories: independent,
slightly impaired, signiﬁcantly impaired, and disabled. Expanding the
CONSORT reporting guideline with this item would further help to
support the search, analysis, synthesis, and interpretation of evidence
in older people not just based on the chronological age but according
to one of the most critical modulators of clinical endpoints in older
people: functional status.
Supplementary Data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jamda.2018.11.008.
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